Effect of Probiotic Supplementation Along With Calorie Restriction on Metabolic Endotoxemia, and Mega Inflammation in Coronary Artery Disease Patients: A Double Blind Placebo Controlled Randomized Clinical Trial

Abstract

Purpose: Dysbiosis has been associated with increased microbial translocation, leading to chronic inflammation in cardiovascular diseases (CVD). It has been proposed that modulation of gut microbiota by probiotic might modify metabolic endotoxemia. Therefore, the purpose of this study was to examine the effects of Lactobacillus rhamnosus GG (LGG) on metabolic endotoxemia, and marker of inflammation in CVD subjects. Methods: This study was a 12-weeks randomized, double-blind, and intervention on 44 patients with CVD. Patients were randomly allocated to receive either one LGG capsule 1.6 ×109 colony-forming unit (CFU) or the placebo capsules for 12 weeks. Serum levels of interleukin-1β (IL-1β), Toll-like receptor 4 (TLR4), interleukin-10 (IL-10), and lipopolysaccharide (LPS), were assessed before and after the intervention. Results: A significant decrease in IL1-Beta concentration (-1.88 ± 2.25, vs. 0.56 ± 1.58 mmol/L, P=0.027), and LPS levels (-5.20 ±2.70 vs. 2.96+ 5.27 mg/L, P=0.016), was observed after the probiotic supplementation compared with the placebo. Subjects who had ≥2.5 kg weight loss showed significantly improved in some variables, compared to patients with <2.5 kg weight reduction, regardless of the supplement they receive.Conclusion: These data provide preliminary evidence that probiotic supplementation has beneficial effects on metabolic endotoxemia, and mega inflammation in subjects with CVD.